Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
time period in Novartis history
|
| gptkbp:CEO |
gptkb:Vas_Narasimhan
gptkb:Joseph_Jimenez |
| gptkbp:endDate |
2019
|
| gptkbp:headquarters |
gptkb:Basel,_Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Novartis (2010–2019)
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableAcquisition |
gptkb:Advanced_Accelerator_Applications
gptkb:Alcon gptkb:AveXis gptkb:Endocyte |
| gptkbp:notableDivestment |
Alcon (spun off in 2019)
|
| gptkbp:notableEvent |
divestment of non-core businesses
focus on innovative medicines increased investment in gene therapy |
| gptkbp:notableProduct |
gptkb:Cosentyx
gptkb:Entresto gptkb:Kymriah gptkb:Zolgensma |
| gptkbp:partOf |
gptkb:Novartis
|
| gptkbp:startDate |
2010
|
| gptkbp:bfsParent |
gptkb:Alcon_Laboratories
|
| gptkbp:bfsLayer |
6
|